Page 18 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 18
Chapter 1
REFERENCES
1. The Collected Papers of Paul Ehrlich. Elsevier; 1960.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity.
Nature. 1975;256:495-497.
3. Katchi T, Liu D. Diagnosis and treatment of CD20 negative B cell lymphomas. Biomarker Research.
2017;5:5.
4. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed
against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147-3154.
5. Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World’s First
Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163.
6. Coiffier B, Lepage E, Brière J, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine. 2002;346:235-242.
7. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190.
8. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24:203-216.
9. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is
associated with an inferior survival. Blood. 2009;113:3773-3780.
10. The Top 15 Best-Selling Drugs of 2017 [Internet]. GEN - Genetic Engineering and Biotechnology News. 2018 [cited 2019 Feb 19]. Available from: https://www.genengnews.com/a-lists/the-top-15- best-selling-drugs-of-2017/
11. Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs. 2019;11:219-238.
12. Matthews H, Hanison J, Nirmalan N. “Omics”-Informed Drug and Biomarker Discovery:
Opportunities, Challenges and Future Perspectives. Proteomes. 2016;4:28.
13. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Ensuring Patient Access to Affordable Drug Therapies. Making Medicines Affordable: A National Imperative. (Nass SJ, Madhavan G, Augustine NR, eds.). Washington (DC): National Academies Press (US); 2017.
14. Van Dongen GA, Huisman MC, Boellaard R, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging. 2015;59:18-38.
15. Verel I, Visser GWM, Boellaard R, et al. 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies. J Nucl Med. 2003;44:1271-1281.
16. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl- desferrioxamine. Nature Protocols. 2010;5:739-743.
17. Graham M, Peterson L, Hayward R. Comparison of simplified quantitative analyses of FDG uptake. Nuclear Medicine and Biology. 2000;27:647-655.
18. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068.
19. Wahl RL, Jacene H, Kasamon Y,et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.
20. O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14:169-186.
16
